IL17A and chronic obstructive pulmonary disease: Subgroup analyses revealed that IL-23 inhibitors were linked to reduced risk of solid tumors (aHR, 0.31; 95% CI, 0.12–0.83), whereas IL-17 inhibitors were associated with increased risk of chronic obstructive pulmonary disease (aHR, 2.96; 95% CI, 1.08–8.14).